Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447279 | 1.00 | KDM1A (0.51) | KDM1AGLA | |
| SCHEMBL16446783 | 0.89 | KDM1A (0.58) | KDM1A | |
| SCHEMBL16455158 | 0.89 | KDM1A (0.58) | KDM1A | |
| SCHEMBL16455163 | 0.88 | KDM1A (0.53) | KDM1A | |
| SCHEMBL16447254 | 0.88 | KDM1A (0.53) | KDM1A | |
| SCHEMBL16447253 | 0.88 | KDM1A (0.53) | KDM1A | |
| SCHEMBL20924673 | 0.87 | KDM1A (0.51) | KDM1A | |
| SCHEMBL16455182 | 0.84 | KDM1A (0.53) | KDM1A | |
| SCHEMBL18016151 | 0.83 | KDM1A (0.56) | KDM1A | |
| SCHEMBL16455070 | 0.82 | KDM1A (0.56) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-3030323-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| CN-105592888-A | Kdm1a inhibitors for the treatment of disease | IMAGO BIOSCIENCES INC | 2016-05-18 | — | — | CN | disclosed |
| WO-2015021128-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015021128-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 2001/4885 |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 1913/4885 |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 2001/4885 |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 2001/4885 |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 2001/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885GLA 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.